Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, cofounder Patrick Hsu, Ph.D., told Fierce Biotech. | Stylus Medicine is ...

Donald Trump has launched a new war, this time against pharmaceutical companies. He has signed an executive order to reduce ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...